Molecular subgroups of medulloblastoma: the current consensus

Medulloblastoma, a small blue cell malignancy of the cerebellum, is a major cause of morbidity and mortality in pediatric oncology. Current mechanisms for clinical prognostication and stratification include clinical factors (age, presence of metastases, and extent of resection) as well as histological subgrouping (classic, desmoplastic, and large cell/anaplastic histology). Transcriptional profiling studies of medulloblastoma cohorts from several research groups around the globe have suggested the existence of multiple distinct molecular subgroups that differ in their demographics, transcriptomes, somatic genetic events, and clinical outcomes. Variations in the number, composition, and nature of the subgroups between studies brought about a consensus conference in Boston in the fall of 2010. Discussants at the conference came to a consensus that the evidence supported the existence of four main subgroups of medulloblastoma (Wnt, Shh, Group 3, and Group 4). Participants outlined the demographic, transcriptional, genetic, and clinical differences between the four subgroups. While it is anticipated that the molecular classification of medulloblastoma will continue to evolve and diversify in the future as larger cohorts are studied at greater depth, herein we outline the current consensus nomenclature, and the differences between the medulloblastoma subgroups.

[1]  Arie Perry,et al.  Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups , 2011, Acta Neuropathologica.

[2]  C. Raffel,et al.  Sporadic Medulloblastomas Contain Oncogenic β-Catenin Mutations , 1998 .

[3]  Roger E. Taylor,et al.  Nodule Formation and Desmoplasia in Medulloblastomas—Defining the Nodular/Desmoplastic Variant and Its Biological Behavior , 2007, Brain pathology.

[4]  Zev A. Binder,et al.  The Genetic Landscape of the Childhood Cancer Medulloblastoma , 2011, Science.

[5]  Jing Yuan,et al.  Interfering with Resistance to Smoothened Antagonists by Inhibition of the PI3K Pathway in Medulloblastoma , 2010, Science Translational Medicine.

[6]  U. Tabori,et al.  Distinctive clinical course and pattern of relapse in adolescents with medulloblastoma. , 2006, International Journal of Radiation Oncology, Biology, Physics.

[7]  Claire L Weston,et al.  beta-Catenin status predicts a favorable outcome in childhood medulloblastoma: the United Kingdom Children's Cancer Study Group Brain Tumour Committee. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  S. Bale,et al.  Patching Together the Genetics of Gorlin Syndrome , 1998, Journal of cutaneous medicine and surgery.

[9]  G. Rao.  The miR-17/92 Polycistron Is Up-regulated in Sonic Hedgehog–Driven Medulloblastomas and Induced by N-myc in Sonic Hedgehog–Treated Cerebellar Neural Precursors , 2010 .

[10]  P. Lichter,et al.  TP53 mutation is frequently associated with CTNNB1 mutation or MYCN amplification and is compatible with long-term survival in medulloblastoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Scott L. Pomeroy,et al.  Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas , 2012, Acta Neuropathologica.

[12]  David T. W. Jones,et al.  Biological and clinical heterogeneity of MYCN-amplified medulloblastoma , 2012, Acta Neuropathologica.

[13]  C. Filley,et al.  Central and Extrapontine Myelinolysis: Then…and Now , 2006, Journal of neuropathology and experimental neurology.

[14]  Roger E. Taylor,et al.  Definition of disease-risk stratification groups in childhood medulloblastoma using combined clinical, pathologic, and molecular variables. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  Paul A. Northcott,et al.  Multiple recurrent genetic events converge on control of histone lysine methylation in medulloblastoma , 2009, Nature Genetics.

[16]  N. Rahman,et al.  Heterogeneity of familial medulloblastoma and contribution of germline PTCH1 and SUFU mutations to sporadic medulloblastoma , 2011, Familial Cancer.

[17]  G. Reifenberger,et al.  Adult and pediatric medulloblastomas are genetically distinct and require different algorithms for molecular risk stratification. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Yiai Tong,et al.  Subtypes of medulloblastoma have distinct developmental origins , 2010, Nature.

[19]  C. Raffel,et al.  Sporadic medulloblastomas contain oncogenic beta-catenin mutations. , 1998, Cancer research.

[20]  Thomas D. Wu,et al.  Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. , 2006, Cancer cell.

[21]  T. Merchant,et al.  Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial. , 2006, The Lancet. Oncology.

[22]  J. Rutka,et al.  Molecular Insight into Medulloblastoma and Central Nervous System Primitive Neuroectodermal Tumor Biology from Hereditary Syndromes: A Review , 2000, Neurosurgery.

[23]  Richard Grundy,et al.  The miR-17/92 polycistron is up-regulated in sonic hedgehog-driven medulloblastomas and induced by N-myc in sonic hedgehog-treated cerebellar neural precursors. , 2009, Cancer research.

[24]  P. Varlet,et al.  Incomplete penetrance of the predisposition to medulloblastoma associated with germ-line SUFU mutations , 2009, Journal of Medical Genetics.

[25]  Hendrik Witt,et al.  Medulloblastoma comprises four distinct molecular variants. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  Webster K. Cavenee,et al.  Erratum: The 2007 WHO classification of tumours of the central nervous system (Acta Neuropathol (2007) vol. 114 (97-109)) , 2007 .

[27]  J. Lowe,et al.  An investigation of WNT pathway activation and association with survival in central nervous system primitive neuroectodermal tumours (CNS PNET) , 2009, British Journal of Cancer.

[28]  T. Curran,et al.  Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  D. Ellison,et al.  Wnt/Wingless Pathway Activation and Chromosome 6 Loss Characterise a Distinct Molecular Sub-Group of Medulloblastomas Associated with a Favourable Prognosis , 2006, Cell cycle.

[30]  M. Hatten,et al.  Development and cancer of the cerebellum , 2011, Trends in Neurosciences.

[31]  Michael L. Gatza,et al.  A pathway-based classification of human breast cancer , 2010, Proceedings of the National Academy of Sciences.

[32]  J. Mesirov,et al.  Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. , 1999, Science.

[33]  R. Wilson,et al.  Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. , 2010, Cancer cell.

[34]  U. Tabori,et al.  Medulloblastoma in the second decade of life: A specific group with respect to toxicity and management , 2005, Cancer.

[35]  R. McLendon,et al.  Identification of OTX2 as a medulloblastoma oncogene whose product can be targeted by all-trans retinoic acid. , 2005, Cancer research.

[36]  Todd R Golub,et al.  Gene expression–based high-throughput screening(GE-HTS) and application to leukemia differentiation , 2004, Nature Genetics.

[37]  M. Clementi,et al.  Identification of a SUFU germline mutation in a family with Gorlin syndrome , 2009, American journal of medical genetics. Part A.

[38]  Axel Benner,et al.  FSTL5 is a marker of poor prognosis in non-WNT/non-SHH medulloblastoma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  D. Ellison,et al.  Rapid Diagnosis of Medulloblastoma Molecular Subgroups , 2011, Clinical Cancer Research.

[40]  Emmanuel Barillot,et al.  Beta‐catenin status in paediatric medulloblastomas: correlation of immunohistochemical expression with mutational status, genetic profiles, and clinical characteristics , 2009, The Journal of pathology.

[41]  C. Rudin,et al.  Smoothened Mutation Confers Resistance to a Hedgehog Pathway Inhibitor in Medulloblastoma , 2009, Science.

[42]  B. Scheithauer,et al.  The 2007 WHO classification of tumours of the central nervous system , 2007, Acta Neuropathologica.

[43]  N. Gerges,et al.  Preponderance of sonic hedgehog pathway activation characterizes adult medulloblastoma , 2011, Acta Neuropathologica.

[44]  Jeremy Stinson,et al.  Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. , 2009, The New England journal of medicine.

[45]  M. Kool,et al.  OTX1 and OTX2 Expression Correlates With the Clinicopathologic Classification of Medulloblastomas , 2006, Journal of neuropathology and experimental neurology.

[46]  Dirk Troost,et al.  Integrated Genomics Identifies Five Medulloblastoma Subtypes with Distinct Genetic Profiles, Pathway Signatures and Clinicopathological Features , 2008, PloS one.

[47]  K. Kinzler,et al.  The molecular basis of Turcot's syndrome. , 1995, The New England journal of medicine.

[48]  T. Poggio,et al.  Prediction of central nervous system embryonal tumour outcome based on gene expression , 2002, Nature.

[49]  Paul A. Northcott,et al.  Pediatric and adult sonic hedgehog medulloblastomas are clinically and molecularly distinct , 2011, Acta Neuropathologica.

[50]  J. Mesirov,et al.  Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  David Hogg,et al.  Mutations in SUFU predispose to medulloblastoma , 2002, Nature Genetics.

[52]  S. Croul,et al.  Adult medulloblastoma comprises three major molecular variants. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  R. McLendon,et al.  OTX2 is critical for the maintenance and progression of Shh-independent medulloblastomas. , 2010, Cancer research.